Sanofi–GSK COVID-19 vaccine
recombinant protein subunit vaccine against COVID-19
The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.
The Sanofi–GSK COVID‑19 vaccine was authorized for medical use in the European Union in November 2022.
Medical uses
The Sanofi–GSK COVID‑19 vaccine is used as a booster for active immunisation against SARS‑CoV‑2 virus in order to prevent COVID‑19.
Pharmacology
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine.
History
The Sanofi–GSK COVID‑19 vaccine is under development by the French pharmaceutical company Sanofi and the British pharmaceutical company GlaxoSmithKline. Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.
Clinical trials
In September 2020, Sanofi-GSK started for phase I trials with 440 participants in the United States.
In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.
On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants, which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico, Nigeria, Pakistan, Sri Lanka, Uganda, and the United States.
In September 2021, Sanofi-GSK started a booster trial in the United Kingdom.
The public source identifies “Sanofi–GSK COVID-19 vaccine” as recombinant protein subunit vaccine against COVID-19. This brief keeps that definition visible, then builds a research path around Sanofi, COVID-19 and vaccine.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Sanofi–GSK COVID-19 vaccine”, the useful work is to connect “recombinant protein subunit vaccine against COVID-19” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 23, 2026. The linked authority identifier is Q106265257. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2022, 2020 and 2021.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Sanofi–GSK COVID-19 vaccine”, its source revision and the description used here.
- Expand the search: follow Sanofi–GSK COVID-19 vaccine primary sources, Sanofi–GSK COVID-19 vaccine archive and Sanofi research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Sanofi–GSK COVID-19 vaccine”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Sanofi–GSK COVID-19 vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.